Strongbridge Biopharma plc News Releases http://investors.strongbridgebio.com/ Strongbridge Biopharma plc News Releases en Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-presents-keveyisr-dichlorphenamide ~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~ DUBLIN, Ireland and TREVOSE, Pa. , May 09, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage Thu, 09 May 2019 16:05:00 -0400 Strongbridge Biopharma plc News Releases 9356 Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-reports-first-quarter-2019-financial ~ Following Type C Meeting with the U.S. Food & Drug Administration ( FDA ), Strongbridge Plans to Submit its New Drug Application (NDA) for RECORLEV™ (levoketoconazole) in the Third Quarter of 2020; Submission to Include Data From the Phase 3 SONICS and LOGICS Studies ~ ~ Newly Presented Data from Wed, 01 May 2019 07:30:00 -0400 Strongbridge Biopharma plc News Releases 9336 Strongbridge Biopharma plc Announces Presentation of New Secondary Endpoint Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists Ann http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-presentation-new-secondary New Analysis Shows RECORLEV™ (levoketoconazole) Significantly Improved Clinician- and Patient-Reported Signs and Symptoms of Cushing’s Syndrome DUBLIN, Ireland and TREVOSE, Pa. , April 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage Thu, 25 Apr 2019 16:01:00 -0400 Strongbridge Biopharma plc News Releases 9331 Strongbridge Biopharma plc to Host First Quarter 2019 Financial Results Conference Call on May 1, 2019 http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-host-first-quarter-2019-financial DUBLIN, Ireland and TREVOSE, Pa. , April 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Wed, 24 Apr 2019 07:30:00 -0400 Strongbridge Biopharma plc News Releases 9326 Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-upcoming-presentation-new-0 DUBLIN, Ireland and TREVOSE, Pa. , April 15, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Mon, 15 Apr 2019 07:30:00 -0400 Strongbridge Biopharma plc News Releases 9316 Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-presentation-new-data-1 ~ Subgroup Analysis of Patients with Comorbid Diabetes Mellitus and Cushing’s Syndrome Presented at Annual Meeting of the Endocrine Society ( ENDO ) Shows Potential Clinical Benefit of Treatment with RECORLEV™ (levoketoconazole) ~ ~ Additional Analyses of RECORLEV Secondary Endpoints Presented at Mon, 25 Mar 2019 07:30:00 -0400 Strongbridge Biopharma plc News Releases 9281 Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-top-line-results-extended ~ Extended Evaluation Phase Meets Objective of Showing Positive Long-Term Benefit-Risk Profile of RECORLEV™ (levoketoconazole) ~ ~ Favorable Liver-Related Findings: No Patients Experienced an Increase in Either Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) of Greater than Three Mon, 11 Mar 2019 07:30:00 -0400 Strongbridge Biopharma plc News Releases 9271 Strongbridge Biopharma plc Announces New Employment Inducement Awards http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-new-employment-inducement-6 DUBLIN, Ireland and TREVOSE, Pa. , March 08, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Fri, 08 Mar 2019 07:30:00 -0500 Strongbridge Biopharma plc News Releases 9256 Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO) http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-upcoming-presentation-new DUBLIN, Ireland and TREVOSE, Pa. , March 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that a Mon, 04 Mar 2019 07:30:00 -0500 Strongbridge Biopharma plc News Releases 9251 Strongbridge Biopharma plc to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference http://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-present-cowen-and-company-39th-annual DUBLIN, Ireland and TREVOSE, Pa. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Wed, 27 Feb 2019 07:30:00 -0500 Strongbridge Biopharma plc News Releases 9231